Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 16/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774914 | 0.90 | CETP (0.56) | CETP | |
| SCHEMBL4775701 | 0.88 | CETP (0.43) | CETPTACR1 | |
| SCHEMBL14410748 | 0.87 | CETP (0.37) | CETPTACR1STS | |
| SCHEMBL3537504 | 0.85 | CETP (0.47) | CETPTACR1SGMS1SGMS2STS | |
| SCHEMBL2127581 | 0.85 | CETP (0.47) | CETPTACR1SGMS1SGMS2STS | |
| SCHEMBL3535990 | 0.85 | CETP (0.47) | CETPTACR1SGMS1SGMS2STS | |
| SCHEMBL14145641 | 0.84 | CETP (0.52) | CETP | |
| SCHEMBL13678925 | 0.83 | CETP (0.44) | CETPTACR1SGMS1SGMS2STS | |
| SCHEMBL3531944 | 0.83 | CETP (0.44) | CETPTACR1SGMS1SGMS2STS | |
| SCHEMBL14145994 | 0.81 | TACR1 (0.40) | CETPTACR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | claimed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | claimed |
| EP-1732933-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097805-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | claimed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | PCSK9, LIPC, APOB | CETP 9/4885TACR1 419/4885SGMS1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.